Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Earnings Data
Report Date
Feb 05, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.43Last Year’s EPS
0.85Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, a solid financial position, and strategic advancements with the proposed acquisition of Merus. However, there were some challenges, including the termination of GEN1042 development in head and neck cancer and a sales miss for EPKINLY. Overall, the positives of strong financial performance and strategic growth initiatives outweigh the negatives.Company Guidance
Significant Revenue Growth
Total revenue grew by 21%, with operating profit increasing by 52%. EPKINLY and TIVDAK sales rose by 54% year-over-year, contributing to 25% of total revenue growth.
Strong Financial Position
Genmab ended the first half with around $3.4 billion in cash, providing a solid financial foundation for continued growth.
Proposed Acquisition of Merus
The acquisition is expected to advance Genmab's evolution into a global biotech leader, adding high potential assets like petosemtamab to the portfolio.
EPKINLY's Market Performance
EPKINLY posted $333 million through Q3, a 64% year-over-year increase, reinforcing its position as a leader in the third-line setting for diffuse large B-cell lymphoma and follicular lymphoma.
Advancements in Rina-S Development
Rina-S showed deep and durable responses in endometrial cancer. The program is progressing with three ongoing Phase III trials.
GMAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GMAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $28.66 | $29.06 | +1.40% |
Aug 07, 2025 | $21.51 | $22.69 | +5.49% |
May 08, 2025 | $20.60 | $19.42 | -5.73% |
Feb 12, 2025 | $18.89 | $19.69 | +4.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Genmab A/S (GMAB) report earnings?
Genmab A/S (GMAB) is schdueled to report earning on Feb 05, 2026, Before Open (Confirmed).
What is Genmab A/S (GMAB) earnings time?
Genmab A/S (GMAB) earnings time is at Feb 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMAB EPS forecast?
GMAB EPS forecast for the fiscal quarter 2025 (Q4) is 0.43.